PSA Biosensor Clinical Trials

Ex-vivo clinical trials completed 2006 in Oslo, Norway

Radium Hospital, Oslo, Norway & Royal Surrey Hospital, Guildford UK have been recruited for in-vivo clinical trials in 2007. Other key centres are currently being identified in Norway and the UK

Radium Hospital, Oslo

"Using the InvivoSense PSA Biosensor under routine TRUS guidance has the potential to improve the clinical staging of Prostate Cancer by detecting early signs of extracapsular (cT3) disease. The value outcome will therefore be to avoid unnecessary treatment procedures and the resulting improvement in the patient's quality of life" Mr. Håkon Wæhre, Consultant, Section of Urology, Dept. of Surgical Oncology, The Norwegian Radium Hospital.

Royal Surrey Hospital, Guildford

CE marking expected in Q1 2008 for the PSA Biosensor

PSA Biosensor | TMS | Company